Rapid Micro Biosystems (RPID) Projected to Post Quarterly Earnings on Friday

Key Points

• Rapid Micro Biosystems will report Q1 2026 results before the market opens on Friday, May 8 (call at 8:30 AM ET), with analysts forecasting ($0.25) EPS and $7.60 million in revenue.
• The company remains unprofitable—last quarter missed EPS estimates at ($0.28), with a negative ROE of 95.4% and net margin of -140.3%, and analysts project about -$1 EPS for the current and next fiscal years; market cap is roughly $109 million and the consensus price target is $8.00 (rating: Hold).
• Insiders have been net sellers recently—about 195,966 shares sold in the last quarter worth ~$781,000 (insiders still own 12.7%); institutional investors hold ~52.6% of the stock.

Rapid Micro Biosystems (NASDAQ:RPID - Get Free Report) will likely be posting its Q1 2026 results before the market opens on Friday, May 8th. Analysts expect the company to announce earnings of ($0.25) per share and revenue of $7.60 million for the quarter. Parties can check the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Friday, May 8, 2026 at 8:30 AM ET.

Rapid Micro Biosystems (NASDAQ:RPID - Get Free Report) last posted its quarterly earnings results on Thursday, March 12th. The company reported ($0.28) earnings per share for the quarter, missing analysts' consensus estimates of ($0.23) by ($0.05). The company had revenue of $11.28 million for the quarter, compared to analyst estimates of $10.93 million. Rapid Micro Biosystems had a negative return on equity of 95.40% and a negative net margin of 140.30%. On average, analysts expect Rapid Micro Biosystems to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Rapid Micro Biosystems Stock Up 4.3%

RPID stock opened at $2.40 on Friday. Rapid Micro Biosystems has a 52 week low of $2.01 and a 52 week high of $4.94. The company has a current ratio of 3.31, a quick ratio of 2.36 and a debt-to-equity ratio of 0.57. The company has a market cap of $109.10 million, a P/E ratio of -2.24 and a beta of 1.59. The company's 50-day moving average price is $2.89 and its 200 day moving average price is $3.37.

Analysts Set New Price Targets

Several equities analysts recently issued reports on RPID shares. Wall Street Zen raised Rapid Micro Biosystems from a "sell" rating to a "hold" rating in a report on Sunday, April 12th. Weiss Ratings reissued a "sell (d-)" rating on shares of Rapid Micro Biosystems in a research note on Tuesday, April 21st. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $8.00.

Insider Transactions at Rapid Micro Biosystems

In other news, CFO Sean M. Wirtjes sold 17,254 shares of the business's stock in a transaction on Friday, February 20th. The shares were sold at an average price of $3.92, for a total value of $67,635.68. Following the sale, the chief financial officer owned 563,674 shares in the company, valued at approximately $2,209,602.08. The trade was a 2.97% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Robert G. Jr. Spignesi sold 38,327 shares of the business's stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $3.89, for a total transaction of $149,092.03. Following the completion of the transaction, the chief executive officer directly owned 1,187,770 shares of the company's stock, valued at $4,620,425.30. This trade represents a 3.13% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 195,966 shares of company stock worth $781,104. Insiders own 12.70% of the company's stock.

Institutional Trading of Rapid Micro Biosystems

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. American Century Companies Inc. increased its position in Rapid Micro Biosystems by 46.1% in the 2nd quarter. American Century Companies Inc. now owns 16,922 shares of the company's stock valued at $58,000 after buying an additional 5,341 shares in the last quarter. OMERS ADMINISTRATION Corp acquired a new position in shares of Rapid Micro Biosystems during the fourth quarter worth approximately $71,000. Barclays PLC bought a new position in shares of Rapid Micro Biosystems in the 4th quarter worth $72,000. XTX Topco Ltd bought a new stake in Rapid Micro Biosystems during the 2nd quarter valued at $144,000. Finally, Goldman Sachs Group Inc. acquired a new position in Rapid Micro Biosystems during the fourth quarter worth $160,000. 52.60% of the stock is currently owned by institutional investors and hedge funds.

About Rapid Micro Biosystems

Rapid Micro Biosystems NASDAQ: RPID develops and commercializes automated microbial detection and contamination control solutions for the life sciences industry. Its flagship offering, the Growth Direct® System, leverages digital imaging and proprietary growth indicator plates to identify and count microorganisms more rapidly than traditional culture-based methods. The company's technology platform is designed to streamline quality control workflows in pharmaceutical, biotechnology and vaccine manufacturing settings, helping clients reduce release times and improve operational efficiency.

In addition to the Growth Direct® System, Rapid Micro Biosystems offers an integrated suite of software and consumables that support automated data capture, analysis and reporting.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.